Algomedix is a biopharmaceutical company focused on developing novel treatment of chronic pain and inflammation. Pricnipals of the firm have discovered and are addressing development of a non-opioid drug that solves the problem of safety, tolorability, abuse and addiction. An arena of focus by Algomedic personnel are novel Transient Receptor Potential (TRP) therapeutics to treat serious medical needs including chronic and acute pain as well as chronic kidney disease. The firm expertise in TRP research has yieleded therapeutic candidates in development having the potential for overcome limitations of current treatment approaches to include a novel non-opioid, non-addictive TRPA1 antagonist for the treatment of pain. This new class of pain therapeutics could potentially overcome the significant shortcomings of opioid drugs with their significant abuse liability and addiction concerns, and non-steroidal anti-inflammatory drugs (NSAIDs) having both safety and tolerability limitations. Algomedix is also advancing a novel TRPC6 therapeutic for the treatment of chronic kidney disease.
